Carcinogenesis Advance Access published online on January 3, 2008
Carcinogenesis, doi:10.1093/carcin/bgm298
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tumor angiogenesis suppression by 
-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor 
1 Laboratory of Biodynamic Chemistry, School of Food, Agricultural and Environment Sciences, Miyagi University, Sendai 982-0215, Japan
2 Department of Nutritional Science, Faculty of Health and Welfare Science, Okayama Prefectural University, 111 Kuboki, Soja, Okayama 719-1197, Japan
* To whom correspondence should be addressed: Tsuyoshi Tsuzuki, PhD, Laboratory of Biodynamic Chemistry, School of Food, Agricultural and Environmental Sciences, Miyagi University, 2-2-1 Hatatate, Taihaku, Sendai 982-0215, Japan. Tel: +81-22-245-1382; Fax: +81-22-245-1534; E-mail: tsuduki{at}myu.ac.jp.
We have previously shown that 
-eleostearic acid (ESA), a linolenic acid isomer with a conjugated triene system, suppresses tumor growth in vivo. In our earlier study, blood vessels were observed at the tumor surface in control mice, whereas in ESA-treated mice no such vessels were observed and the inner part of the tumor was discolored. These observations suggested that ESA might suppress cancer cell growth through malnutrition via a suppressive effect on tumor angiogenesis. In the current study, the antiangiogenic effects of ESA were investigated in vivo and in vitro. Tumor cell-induced vessel formation was clearly suppressed in mice orally administered ESA at doses of 50 and 100 mg/kg/day in a dose-dependent manner. ESA also inhibited the formation of capillary-like networks by human umbilical vein endothelial cells (HUVEC) and moderately inhibited HUVEC proliferation and migration in a dose-dependent manner. The mechanism by which ESA inhibited angiogenesis was through suppression of the expression of vascular endothelial growth factor (VEGF) receptors 1 and 2, activation of peroxisome proliferator-activated receptor (PPAR) 
, and induction of apoptosis in HUVEC. We thus demonstrated that, like troglitazone, ESA is a PPAR ligand, and that it activates PPAR, induces apoptosis in HUVEC, and inhibits angiogenesis. Our findings suggest that ESA has potential use as a therapeutic dietary supplement and medicine for minimizing tumor angiogenesis.
Key Words: angiogenesis • eleostearic acid • conjugated fatty acid • conjugated linoleic acid • PPAR
Received October 31, 2007; revised December 16, 2007; accepted December 16, 2007.